Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)
Key Information
Due Date: July 1, 2024
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Grant
Match Required: No
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
Applications are invited for the Exploratory/Developmental Phased Innovation (R61/R33) grant to fund the development of these necessary clinical trials. The anticipated research should be guided by measurable, milestone-driven objectives.
The grant will cover a total project period of up to five years. An initial two-year phase (R61) is provided for preliminary, exploratory, and planning studies. This can potentially transition into a clinical trial stage (R33), with support for an additional three years.
However, it is important to note that despite the phases, the total duration of the entire grant, including both R61 and R33 stages, should not exceed five years. Moreover, the initial two-year R61 phase is dependent on established, measurable milestones.
Key Dates
Open Date: April 5, 2022
Application Due Date: July 1, 2024
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses